Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ELAB

PMGC Holdings Inc

Dec 24 • 04:00PM ET

2.35

Dollar change -0.26
Percentage change -9.96	%

Healthcare • Biotechnology • USA • NASD

Peers: LLY JNJ PFE MRK GILD AMGN BMY ABBV VRTX REGN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-58.48	Insider Own	1.63%	Shs Outstand	3.07M	Perf Week	19.29%
Market Cap	7.22M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.02M	Perf Month	-41.54%
Income	-5.47M	PEG	-	EPS next Q	-	Inst Own	1.21%	Short Float	8.71%	Perf Quarter	-88.81%
Sales	2.45M	P/S	2.95	EPS this Y	-	Inst Trans	-	Short Ratio	0.21	Perf Half Y	-97.99%
Book/sh	34.65	P/B	0.07	EPS next Y	-	ROA	-85.53%	Short Interest	0.26M	Perf Year	-99.36%
Cash/sh	2.09	P/C	1.12	EPS next 5Y	-	ROE	-130.35%	52W Range	1.74 - 778.00	Perf YTD	-99.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-63.92%	52W High	-99.70%	Beta	-2.94
Dividend TTM	-	Quick Ratio	3.40	Sales past 5Y	46340.47%	Gross Margin	70.00%	52W Low	35.04%	ATR (14)	0.87
Dividend Ex-Date	-	Current Ratio	3.86	EPS Y/Y TTM	-	Oper. Margin	-207.86%	RSI (14)	32.74	Volatility	27.09% 20.22%
Employees	18	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-223.57%	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	13.27%	Payout	-	Rel Volume	0.31	Prev Close	2.61
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-4.90%	Earnings	Aug 14 BMO	Avg Volume	1.24M	Price	2.35
SMA20	4.47%	SMA50	-67.11%	SMA200	-96.89%	Trades		Volume	380,783	Change	-9.96%

Dec-21-24 07:40AM	Elevai Labs plans name change to PMGC Holdings, redomicile to Nevada (TipRanks)
Dec-20-24 07:30PM	Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada (GlobeNewswire) +8.94%
07:30AM	Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada (GlobeNewswire)
Dec-09-24 08:00AM	Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation (GlobeNewswire)
Dec-06-24 07:30AM	Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market (GlobeNewswire)
08:00AM	Loading…
Dec-04-24 08:00AM	Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division (GlobeNewswire) +5.03%
Nov-22-24 06:23PM	Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance (GlobeNewswire) -20.90%
05:00PM	Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess (GlobeNewswire)
Nov-14-24 02:35PM	CORRECTION - Elevai Labs Inc. (GlobeNewswire) +6.07%
09:08AM	Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update (GlobeNewswire)
Nov-04-24 05:45PM	Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange (GlobeNewswire) -30.45% +6.47%
Oct-22-24 09:54AM	Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity (GlobeNewswire)
Oct-21-24 07:30AM	Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity (GlobeNewswire) +6.34%
Oct-04-24 05:08PM	Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock (GlobeNewswire) -18.18%
Oct-03-24 03:45PM	REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations (GlobeNewswire) +54.93%
07:30AM	Loading…
07:30AM	Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations (GlobeNewswire)
Oct-02-24 08:30AM	Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device (GlobeNewswire)
Sep-26-24 09:42PM	Altium Capital Management LP Acquires New Stake in Elevai Labs Inc (GuruFocus.com) -15.24%
Sep-24-24 05:00PM	Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB) (GlobeNewswire)
Sep-23-24 08:45AM	Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering (GlobeNewswire) -62.00%
Sep-10-24 07:30AM	Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications (GlobeNewswire)
Sep-03-24 07:30AM	Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology (GlobeNewswire) +20.12%
Aug-28-24 07:30AM	Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBio? Y100 Mitochondrial Innovation and Elevai Exosomes (GlobeNewswire) -12.28%
Aug-26-24 07:30AM	Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity Topical Exosome Serum (GlobeNewswire)
Aug-19-24 09:00AM	Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications (GlobeNewswire)
Aug-14-24 09:05AM	Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.60%
Jul-30-24 09:00AM	Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD (GlobeNewswire)
Jun-28-24 09:00AM	Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line (GlobeNewswire)
Jun-26-24 09:00AM	Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024 (GlobeNewswire)
Jun-14-24 09:00AM	Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs (GlobeNewswire) -5.10%
09:00AM	Loading…
May-29-24 09:00AM	Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm (GlobeNewswire)
May-22-24 04:15PM	Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference (GlobeNewswire)
May-15-24 10:53PM	ELAB Stock Earnings: Elevai Labs Reported Results for Q1 2024 (InvestorPlace)
04:30PM	Elevai Labs Inc. Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 08:30AM	Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset EL-22 for The Treatment of Obesity (GlobeNewswire) +8.13%
May-01-24 04:00PM	Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare (GlobeNewswire) -6.95%
09:00AM	Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments (GlobeNewswire)
Apr-29-24 09:45AM	Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments (GlobeNewswire) +7.62%
Apr-22-24 12:08PM	Elevai Labs Signs Exclusive Distribution Deal for Taiwan (MT Newswires)
08:00AM	ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months (GlobeNewswire)
Apr-02-24 08:52AM	ELAB Stock Earnings: Elevai Labs Reported Results for Q4 2023 (InvestorPlace)
Mar-29-24 12:00PM	Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results (GlobeNewswire)
Mar-28-24 01:38PM	15 Best Beauty Stocks To Invest In (Insider Monkey)
Mar-18-24 08:30AM	Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market (GlobeNewswire) +9.03%
Feb-01-24 08:00AM	Why Is Elevai Labs (ELAB) Stock Up 57% Today? (InvestorPlace) +21.56%
Jan-24-24 08:30AM	ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office (GlobeNewswire) -10.00%
Jan-17-24 08:30AM	ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach (GlobeNewswire) -21.58%
Jan-16-24 01:48PM	Why Is Elevai Labs (ELAB) Stock Up Today? (InvestorPlace) -18.71%
08:30AM	ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology (GlobeNewswire)
Jan-02-24 09:15AM	ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences (GlobeNewswire)
Dec-12-23 05:51AM	ELAB Stock Earnings: Elevai Labs Reported Results for Q3 2024 (InvestorPlace) -6.49%
Dec-11-23 09:15AM	Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023 (GlobeNewswire) -10.19%
Dec-07-23 09:41AM	ELEVAI Labs, Inc. Expands International Distribution into Europe (GlobeNewswire) -9.75%
Nov-29-23 09:00AM	Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products (GlobeNewswire) -12.25%
Nov-24-23 12:00PM	Univest Securities, LLC Announces Closing of $6 Million Initial Public Offering of Common Stock for its Client ELEVAI Labs Inc. (Nasdaq: ELAB) (GlobeNewswire) +6.63%
11:15AM	ELEVAI Labs, Inc. Announces Closing of $6,000,000 Initial Public Offering (PR Newswire)

PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed and Jordan R. Plews in 2020 and is headquartered in Newport Beach, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELAB

PMGC Holdings Inc

Upgrade your FINVIZ experience